BR112016013420A2 - células eucarióticas e métodos para expressar recombinantemente um produto de interesse - Google Patents

células eucarióticas e métodos para expressar recombinantemente um produto de interesse

Info

Publication number
BR112016013420A2
BR112016013420A2 BR112016013420A BR112016013420A BR112016013420A2 BR 112016013420 A2 BR112016013420 A2 BR 112016013420A2 BR 112016013420 A BR112016013420 A BR 112016013420A BR 112016013420 A BR112016013420 A BR 112016013420A BR 112016013420 A2 BR112016013420 A2 BR 112016013420A2
Authority
BR
Brazil
Prior art keywords
interest
product
methods
eukaryotic cells
recombinantly expressing
Prior art date
Application number
BR112016013420A
Other languages
English (en)
Inventor
Ritter Anett
Laux Holger
Jostock Thomas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52278688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016013420(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016013420A2 publication Critical patent/BR112016013420A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se à célula eucariótica adequada para produção recombinante de um produto de interesse, onde o genoma da célula hospedeira é alterado de maneira que o efeito da proteína fam60a é prejudicado na dita célula, por exemplo, através da redução ou eliminação de expressão funcional do gene fam60a, desta maneira, aperfeiçoando as características de estabilidade. ainda, a presente invenção provê tecnologias associadas onde tais células hospedeiras são usadas em tecnologias de produção recombinante.
BR112016013420A 2013-12-20 2014-12-18 células eucarióticas e métodos para expressar recombinantemente um produto de interesse BR112016013420A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361919340P 2013-12-20 2013-12-20
PCT/IB2014/067076 WO2015092737A1 (en) 2013-12-20 2014-12-18 Novel eukaryotic cells and methods for recombinantly expressing a product of interest

Publications (1)

Publication Number Publication Date
BR112016013420A2 true BR112016013420A2 (pt) 2017-09-26

Family

ID=52278688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013420A BR112016013420A2 (pt) 2013-12-20 2014-12-18 células eucarióticas e métodos para expressar recombinantemente um produto de interesse

Country Status (18)

Country Link
US (2) US11242551B2 (pt)
EP (2) EP3083677B1 (pt)
JP (1) JP6709156B2 (pt)
KR (1) KR102288232B1 (pt)
CN (1) CN106029691A (pt)
AU (1) AU2014369177B2 (pt)
BR (1) BR112016013420A2 (pt)
CA (1) CA2934412C (pt)
DK (1) DK3083677T3 (pt)
ES (1) ES2758505T3 (pt)
IL (1) IL245856B (pt)
LT (1) LT3083677T (pt)
MX (1) MX2016008258A (pt)
PL (1) PL3083677T3 (pt)
PT (1) PT3083677T (pt)
RU (1) RU2712507C2 (pt)
SG (1) SG11201604218RA (pt)
WO (1) WO2015092737A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029692A (zh) 2013-12-20 2016-10-12 诺华股份有限公司 用于重组表达感兴趣产物的新型真核细胞和方法
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CN108018302A (zh) * 2016-10-31 2018-05-11 三生国健药业（上海）股份有限公司 一种高表达外源蛋白稳定细胞株的筛选方法
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN107723276B (zh) * 2017-11-02 2021-08-13 上海交通大学 一种稳定高表达目标产物的细胞株的构建方法和试剂盒
EP3717640A1 (en) 2017-11-28 2020-10-07 Danmarks Tekniske Universitet Glycosylation of proteins
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
EP4430069A1 (en) 2021-11-09 2024-09-18 Danmarks Tekniske Universitet Variants of alpha-1-antitrypsin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585532B2 (ja) 1986-05-10 1997-02-26 三井東圧化学株式会社 動物細胞の形質転換体及びそれを得る方法並びにその形質転換体を用いてｔ−ＰＡを生産する方法
DE69128037T2 (de) 1990-11-13 1998-05-07 Immunex Corp., Seattle, Wash. Bifunktionelle wählbare fusionsgene
AU660671B2 (en) 1991-03-29 1995-07-06 Genentech Inc. Methods for selection of recombinant host cells expressing high levels of a desired protein
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JP4031154B2 (ja) * 1999-07-30 2008-01-09 独立行政法人科学技術振興機構 遺伝子増幅細胞の迅速選択法
JP2004538002A (ja) 2001-08-02 2004-12-24 アルタナ　ファルマ　アクチエンゲゼルシャフト 停止コドン抑制による組み換え遺伝子発現の新規方法
US20050221325A1 (en) 2002-05-22 2005-10-06 Greg Thill Detection of secreted polypeptides
WO2004035732A2 (en) * 2002-08-29 2004-04-29 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
JP5171033B2 (ja) 2003-03-11 2013-03-27 メルク セローノ ソシエテ アノニム ｍＣＭＶＩＥ２プロモーターを含んで成る発現ベクター
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
WO2005073375A1 (en) 2004-01-30 2005-08-11 Maxygen Holdings Ltd. Regulated stop codon readthrough
US20050272061A1 (en) 2004-02-19 2005-12-08 Seattle Genetics, Inc. Expression profiling in non-small cell lung cancer
IL165484A0 (en) 2004-11-30 2006-01-15 Applied Research Systems Production of proteins
ES2573027T3 (es) 2006-05-17 2016-06-03 F. Hoffmann-La Roche Ag Células productoras de polipéptido
EP2078075B1 (en) 2006-10-30 2015-09-02 Eli Lilly and Company Random homozygous gene perturbation to enhance antibody production
US20080116234A1 (en) 2006-11-17 2008-05-22 3M Innovative Properties Company Ribbon curling device
EA018840B1 (ru) 2007-02-15 2013-11-29 ДСМ АйПи АССЕТС Б.В. Рекомбинантная клетка-хозяин для получения соединения, представляющего интерес
CN101765660B (zh) 2007-05-22 2013-10-23 巴斯夫植物科学有限公司 具有提高的环境胁迫耐受性和/或抗性和提高的生物量生产的植物细胞和植物
MX2010001319A (es) 2007-08-07 2010-06-01 Chugai Pharmaceutical Co Ltd Metodo para producir proteinas heterogeneas.
CN101903526B (zh) 2007-12-21 2014-02-12 诺华股份有限公司 有机化合物
PL2329020T3 (pl) 2008-08-28 2013-08-30 Novartis Ag Prezentacja izoform polipeptydu na powierzchni komórki poprzez nadczytywanie kodonu stop
SG173456A1 (en) 2009-02-27 2011-09-29 Novartis Ag Expression vector system comprising two selection markers
JP2012526535A (ja) 2009-05-15 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＮｏＣＲの発現が低下した改良細胞系及びその使用
CN106029692A (zh) 2013-12-20 2016-10-12 诺华股份有限公司 用于重组表达感兴趣产物的新型真核细胞和方法

Also Published As

Publication number Publication date
IL245856B (en) 2021-06-30
MX2016008258A (es) 2016-09-29
JP2016540518A (ja) 2016-12-28
CA2934412C (en) 2024-02-20
WO2015092737A1 (en) 2015-06-25
RU2016129278A (ru) 2018-01-25
KR102288232B1 (ko) 2021-08-10
PL3083677T3 (pl) 2020-03-31
AU2014369177A1 (en) 2016-06-16
CA2934412A1 (en) 2015-06-25
KR20160099675A (ko) 2016-08-22
US11242551B2 (en) 2022-02-08
RU2712507C2 (ru) 2020-01-29
US20220325310A1 (en) 2022-10-13
IL245856A0 (en) 2016-07-31
US20170058307A1 (en) 2017-03-02
PT3083677T (pt) 2019-12-02
ES2758505T3 (es) 2020-05-05
CN106029691A (zh) 2016-10-12
SG11201604218RA (en) 2016-07-28
EP3083677B1 (en) 2019-08-28
JP6709156B2 (ja) 2020-06-10
EP3083677A1 (en) 2016-10-26
DK3083677T3 (da) 2019-11-25
EP3604332A1 (en) 2020-02-05
LT3083677T (lt) 2019-12-10
AU2014369177B2 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
BR112016013420A2 (pt) células eucarióticas e métodos para expressar recombinantemente um produto de interesse
BR112016013443A2 (pt) células eucarióticas e métodos para expressar recombinantemente um produto de interesse
BR112016023559A2 (pt) mutações de deleção
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
BR112016023188A2 (pt) uso de um polipeptídeo, composição detergente, métodos de lavagem para a lavagem de um item e de produção do polipeptídeo, polipeptídeo isolado, construção de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, formulação de caldo inteiro ou composição de cultura de células
BR112017011542A2 (pt) produção de ácido oleico em levedura
BR112018076126A2 (pt) compostos heterocíclicos como antibacterianos
CO7051009A2 (es) Composiciones del factor viii y métodos para hacerlas y usarlas
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
BR112014030202A2 (pt) microorganismos e métodos para a produção de 4-hidroxibutirato 1,4-butanodiol e compostos relacionados
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112016001457A2 (pt) Inibidores de fatores de transcrição e usos dos mesmos
BR112014019601A2 (pt) método para a produção de uma planta tendo uma resistência melhorada à seca, usos de uma sequência de aminoácido, de pelo menos uma parte de uma sequência de ácido nucleico, de uma proteína, e de uma planta, célula de planta, ou produto de planta, e, planta, célula de planta ou produto de planta
BR112017013394A2 (pt) fabricação de proteína
BR112014026206A2 (pt) sistemas e métodos celulares para melhorar a síntese de ácidos graxos através da expressão da desidrogenase
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112016011096A2 (pt) Aplicação de laminina à cultura de célula endotelial da córnea
BR112018011896A2 (pt) promotor, ácido nucleico, célula hospedeira procariótica, método de fermentação, e, método para aumentar a expressão ou atividade de catalase em uma célula hospedeira procariótica
BR112013030824A8 (pt) Bactéria gram-positiva, ácido necleico recombinante, composição farmacêutica e vetor
BR112016016342A2 (pt) Polipeptídeo variante que tem atividade de lactase, sequência de ácido nucleico, construto de ácido nucleico, vetor de expressão recombinante, método para produzir uma lactase, método para produzir uma variante de polipeptídeo de lactase, composição, uso de um polipeptídeo variante, processo para a produção de um produto lácteo e produto lácteo
BR112017010010A2 (pt) método para produzir 3-oxo-5-hidroxipentanoil-coa, método para biossintetizar 1,3-butanodiol, hospedeiro recombinante, produto bioderivado, produto biobaseado ou produto derivado de fermentação, retícula bioquímica de ocorrência não natural, construto de ácido nucleico ou vetor de expressão e composição
BR112015021210B8 (pt) Método para reduzir a expressão de um ácido nucleico alvo em uma planta e ácido nucleico recombinante
BR112016015678A2 (pt) Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements